SMN2 and proximal spinal muscular atrophy: The committee noted that the company’s and EAG’s base-case analyses, the SMN2 gene copy number subgroup analysis, and the EAG’s scenario analyses all indicated that onasemnogene abeparvovec for pre-symptomatic SMA dominated (1) onasemnogene abeparvovec for type 1 SMA, and (2) BSC for type 2 SMA and type 3 SMA.